Clinical trial
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
NCT00077012 · QLT Inc., Industry · Completed
Key facts
| NCT number | NCT00077012 |
|---|---|
| Title | Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia |
| Official title | A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Transurethral Photodynamic Therapy With QLT0074 for Benign Prostatic Hyperplasia |
| Lead sponsor | QLT Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia |
| Intervention type | Drug |
| Interventions | QLT0074, Photodynamic therapy |
| Start date | Mar 1, 2003 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Feb 11, 2004 |
| Last update posted | May 23, 2012 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: